Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2023 08:30 ET | Source: PainReform Ltd

PainReform CEO to Present at Aegis Virtual Conference on May 4th

TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
May 01, 2023 08:30 ET | Source: PainReform Ltd

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
April 17, 2023 09:00 ET | Source: PainReform Ltd

PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th

TEL AVIV, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
March 28, 2023 09:10 ET | Source: PainReform Ltd

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
March 16, 2023 08:00 ET | Source: PainReform Ltd

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

TEL AVIV, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
March 14, 2023 08:00 ET | Source: PainReform Ltd

PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, March 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
February 07, 2023 16:05 ET | Source: PainReform Ltd

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement

TEL AVIV, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
November 15, 2022 08:30 ET | Source: PainReform Ltd

PainReform Provides Business Update for the Third Quarter of 2022

TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
November 08, 2022 08:30 ET | Source: PainReform Ltd

PainReform Provides Further Update on Manufacturing of PRF-110

TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
October 04, 2022 09:00 ET | Source: PainReform Ltd

PainReform Provides PRF-110 Manufacturing Update

Completed tech transfer to CMO resulting in new process improvements On track to commence Phase 3 clinical trial in bunionectomy in November 2022 TEL AVIV, Israel, Oct. 04, 2022 (GLOBE NEWSWIRE)...